Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study
Article in BMC Cancer (November 2020)
The most recent citing publications are shown below. View all 37 publications that cite this research output on Dimensions.
Article in BMC Cancer (November 2020)
Preprint in Research Square (April 2020)
Article in Molecular Cancer Research (May 2017)